Loading company…
San Diego-based Reneo Pharmaceuticals develops therapies for mitochondrial diseases and rare metabolic disorders, including REN001.
Founded in 2014 and headquartered in San Diego, US, Reneo Pharmaceuticals, Inc. develops therapeutics for mitochondrial diseases and rare metabolic disorders. Its pipeline includes REN001, under study for primary mitochondrial myopathies, fatty acid oxidation disorders and McArdle disease. The company has raised a total of USD 5.00 mn, most recently in a private placement in May 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in